JP6859347B2 - 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法 - Google Patents

単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法 Download PDF

Info

Publication number
JP6859347B2
JP6859347B2 JP2018526984A JP2018526984A JP6859347B2 JP 6859347 B2 JP6859347 B2 JP 6859347B2 JP 2018526984 A JP2018526984 A JP 2018526984A JP 2018526984 A JP2018526984 A JP 2018526984A JP 6859347 B2 JP6859347 B2 JP 6859347B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
sdab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525033A5 (enExample
JP2018525033A (ja
Inventor
ファン，シャオフー
チョウ，チュアン−チュ
ジュアン，チーチュアン
ワン，ピンヤン
ワン，リン
ヤン，レイ
ハオ，ジャーイン
Original Assignee
レジェンド バイオテック アイルランド リミテッド
レジェンド バイオテック アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジェンド バイオテック アイルランド リミテッド, レジェンド バイオテック アイルランド リミテッド filed Critical レジェンド バイオテック アイルランド リミテッド
Publication of JP2018525033A publication Critical patent/JP2018525033A/ja
Publication of JP2018525033A5 publication Critical patent/JP2018525033A5/ja
Priority to JP2021052453A priority Critical patent/JP7168173B2/ja
Application granted granted Critical
Publication of JP6859347B2 publication Critical patent/JP6859347B2/ja
Priority to JP2022167222A priority patent/JP2022183283A/ja
Priority to JP2024014929A priority patent/JP2024032975A/ja
Priority to JP2025134318A priority patent/JP2025159117A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018526984A 2015-08-11 2016-08-10 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法 Active JP6859347B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021052453A JP7168173B2 (ja) 2015-08-11 2021-03-25 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2022167222A JP2022183283A (ja) 2015-08-11 2022-10-18 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2024014929A JP2024032975A (ja) 2015-08-11 2024-02-02 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2025134318A JP2025159117A (ja) 2015-08-11 2025-08-12 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510490002 2015-08-11
CN201510490002.8 2015-08-11
CN201510733585.2 2015-11-02
CN201510733585.2A CN105384825B (zh) 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PCT/CN2016/094408 WO2017025038A1 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021052453A Division JP7168173B2 (ja) 2015-08-11 2021-03-25 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2018525033A JP2018525033A (ja) 2018-09-06
JP2018525033A5 JP2018525033A5 (enExample) 2020-06-18
JP6859347B2 true JP6859347B2 (ja) 2021-04-14

Family

ID=55417644

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2018526984A Active JP6859347B2 (ja) 2015-08-11 2016-08-10 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2021052453A Active JP7168173B2 (ja) 2015-08-11 2021-03-25 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2022167222A Pending JP2022183283A (ja) 2015-08-11 2022-10-18 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2024014929A Withdrawn JP2024032975A (ja) 2015-08-11 2024-02-02 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2025134318A Pending JP2025159117A (ja) 2015-08-11 2025-08-12 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2026058173A Pending JP2026099826A (ja) 2015-08-11 2026-03-31 Ｂｃｍａを標的とするキメラ抗原受容体及びその使用方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2021052453A Active JP7168173B2 (ja) 2015-08-11 2021-03-25 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2022167222A Pending JP2022183283A (ja) 2015-08-11 2022-10-18 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2024014929A Withdrawn JP2024032975A (ja) 2015-08-11 2024-02-02 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2025134318A Pending JP2025159117A (ja) 2015-08-11 2025-08-12 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2026058173A Pending JP2026099826A (ja) 2015-08-11 2026-03-31 Ｂｃｍａを標的とするキメラ抗原受容体及びその使用方法

Country Status (37)

Country Link
US (2) US10934363B2 (enExample)
EP (5) EP4755460A2 (enExample)
JP (6) JP6859347B2 (enExample)
KR (2) KR20240173368A (enExample)
CN (9) CN105384825B (enExample)
AU (4) AU2016305075B2 (enExample)
BR (1) BR112018002844A2 (enExample)
CA (1) CA2994579C (enExample)
CL (4) CL2018000378A1 (enExample)
CO (2) CO2018001405A2 (enExample)
CR (2) CR20210225A (enExample)
CY (1) CY2024032I2 (enExample)
DK (2) DK4063397T3 (enExample)
EA (1) EA201890302A1 (enExample)
ES (3) ES3067089T3 (enExample)
FI (3) FI4063397T3 (enExample)
FR (1) FR24C1050I2 (enExample)
HR (2) HRP20260300T1 (enExample)
HU (3) HUE067869T2 (enExample)
IL (3) IL294683A (enExample)
LT (4) LT4063397T (enExample)
MX (2) MX2018001739A (enExample)
MY (3) MY188362A (enExample)
NL (1) NL301301I2 (enExample)
NO (1) NO2024054I1 (enExample)
NZ (1) NZ750366A (enExample)
PH (2) PH12018500295B1 (enExample)
PL (3) PL3334765T3 (enExample)
PT (2) PT4063397T (enExample)
RS (3) RS68082B1 (enExample)
SA (2) SA518390904B1 (enExample)
SG (2) SG10201913485QA (enExample)
SI (2) SI3334765T1 (enExample)
SM (3) SMT202600176T1 (enExample)
UA (2) UA125818C2 (enExample)
WO (1) WO2017025038A1 (enExample)
ZA (2) ZA201800703B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021094037A (ja) * 2015-08-11 2021-06-24 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
US12351638B2 (en) 2016-08-10 2025-07-08 Legend Biotech Usa Inc. Chimeric antigen receptors targeting BCMA and methods of use thereof

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
CN104004095B (zh) * 2014-06-04 2016-11-23 博生吉医药科技(苏州)有限公司 一种cd7纳米抗体、其编码序列及应用
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
CN110699371A (zh) * 2016-03-18 2020-01-17 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
KR102427334B1 (ko) * 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018014039A1 (en) * 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
WO2018014122A1 (en) * 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
CN106755108A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
CN106755109A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
EP3581190B1 (en) 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
CN106822184A (zh) * 2016-12-15 2017-06-13 梁爱斌 多靶点联合的car‑t细胞制剂与制备方法
EP3559035A1 (en) * 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN106749677B (zh) * 2017-01-04 2020-06-12 上海交通大学医学院附属瑞金医院 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
WO2018200582A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
PL3618842T3 (pl) 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
EP3624834A1 (en) * 2017-05-17 2020-03-25 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
CN107299110B (zh) 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107245500B (zh) * 2017-05-27 2019-05-17 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
JP7240335B2 (ja) * 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019006072A1 (en) * 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN109232742B (zh) * 2017-07-11 2021-10-22 深圳市第二人民医院 一种嵌合抗原受体及其应用
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
WO2019018525A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123
AU2018309735B2 (en) * 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
US20200207867A1 (en) * 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
WO2019066435A2 (ko) 2017-09-29 2019-04-04 재단법인 목암생명과학연구소 Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) * 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
CA3082297A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
US20190192678A1 (en) * 2017-12-18 2019-06-27 Novather, Inc. System and method for the treatment of disease using a hyperspecific modified protein system
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
MA51428A (fr) * 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN108285486A (zh) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
CN108341881B (zh) * 2018-01-31 2020-08-18 深圳市默赛尔生物医学科技发展有限公司 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108314739B (zh) * 2018-02-05 2020-07-14 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN110129369B (zh) * 2018-02-09 2023-10-13 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN108220247A (zh) * 2018-03-20 2018-06-29 杭州史迪姆生物科技有限公司 一种双car-t细胞及其制备方法和应用
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
WO2019220368A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
CN110606893B (zh) * 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
LT3823990T (lt) * 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
SG11202101415UA (en) * 2018-08-10 2021-03-30 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
CN109134665B (zh) 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
CN111542343B (zh) * 2018-08-24 2023-08-18 上海先博生物科技有限公司 抗bcma的单域抗体及其应用
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
WO2020052543A1 (en) * 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
CN109293781A (zh) * 2018-09-12 2019-02-01 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
CN109081870B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
WO2020061796A1 (en) * 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
WO2020087065A1 (en) * 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
US12466892B2 (en) 2018-11-08 2025-11-11 The Regents Of The University Of California Systems and methods for targeting cancer cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN110951689A (zh) * 2018-11-30 2020-04-03 北京美康基免生物科技有限公司 一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
CN109651511B (zh) * 2018-12-26 2020-06-09 广州百暨基因科技有限公司 一种靶向bcma的嵌合抗原受体及其应用
US20220144960A1 (en) * 2018-12-26 2022-05-12 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CN109652379B (zh) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
WO2020154150A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113330038A (zh) * 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
EP3920693A4 (en) * 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
CN113613664B (zh) 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959307A4 (en) * 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
EP3966245A1 (en) * 2019-05-04 2022-03-16 Inhibrx, Inc. Cd33-binding polypeptides and uses thereof
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
CN114341365A (zh) * 2019-08-30 2022-04-12 詹森生物科技公司 B细胞成熟复合物car t构建体和引物
CN114667294B (zh) * 2019-09-02 2024-04-16 成都盛世君联生物技术有限公司 特异性结合b细胞成熟抗原的抗体及其用途
CN112739721B (zh) * 2019-09-26 2023-01-31 苏州克睿基因生物科技有限公司 一种单域抗体及包含抗体结构的嵌合抗原受体
WO2021081133A1 (en) * 2019-10-21 2021-04-29 Purdue Research Foundation Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
CA3156761A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
WO2021105989A1 (en) * 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
WO2021105988A1 (en) 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
CN114829405B (zh) * 2019-12-10 2025-07-18 爱必乐生物公司 抗bcma/抗4-1bb双特异性抗体及其用途
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
EP4077398A4 (en) * 2019-12-16 2024-04-10 Legend Biotech Ireland Limited SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETTING BCMA AND METHODS OF USE THEREOF
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CN111196858B (zh) * 2020-02-05 2021-02-09 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN113248620A (zh) * 2020-02-13 2021-08-13 四川大学 一种嵌合抗原受体的共刺激信号结构域及其应用
CN115698285A (zh) * 2020-02-14 2023-02-03 小利兰·斯坦福大学董事会 具有cd2激活的嵌合抗原受体
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
CN115768899B (zh) 2020-03-09 2026-03-27 詹森生物科技公司 用于定量重组载体核酸整合的组合物和方法
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
CA3181399A1 (en) 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
EP3915576A1 (en) * 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
CN111574629B (zh) * 2020-06-01 2021-07-20 宁夏医科大学 一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
JP2023530039A (ja) 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
WO2022011531A1 (zh) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CN116390941A (zh) * 2020-07-16 2023-07-04 南京传奇生物科技有限公司 多特异性嵌合抗原受体及其用途
US20230250184A1 (en) * 2020-07-16 2023-08-10 Nanjing Legend Biotech Co., Ltd. Cd22 binding molecules and uses thereof
JP7846667B2 (ja) * 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
CA3186065A1 (en) * 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
CN111848798B (zh) * 2020-07-27 2022-05-13 源道隆（苏州）医学科技有限公司 可结合bcma的纳米抗体及其应用
AU2021317073A1 (en) * 2020-07-29 2023-02-16 National Research Council Of Canada Anti-CD22 single domain antibodies and therapeutic constructs
US20230340146A1 (en) 2020-08-13 2023-10-26 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
EP4201960A4 (en) * 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
WO2022116086A1 (en) * 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20240059794A1 (en) * 2020-12-17 2024-02-22 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
CA3209218A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
WO2022183160A1 (en) * 2021-02-25 2022-09-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods for treating cd83-expressing cancer
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
CN115109156B (zh) * 2021-03-22 2024-03-08 浙江纳米抗体技术中心有限公司 一种靶向bcma的纳米抗体及其应用
PE20260568A1 (es) * 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
CN117337303A (zh) * 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
CN118201618A (zh) 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022228579A1 (en) * 2021-04-30 2022-11-03 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting gpc3 and methods of use thereof
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
IL308345A (en) 2021-05-11 2024-01-01 Janssen Biotech Inc Methods for Minimizing Neurotoxicity Associated with Chimeric Antigen Receptor (CAR) T Cell Therapy
CN117425670A (zh) * 2021-05-19 2024-01-19 细胞编辑有限责任公司 双特异性嵌合抗原受体和表达此类双特异性嵌合抗原受体的基因工程化免疫细胞
CA3216228A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CN113651893B (zh) * 2021-08-12 2023-08-01 上海生物制品研究所有限责任公司 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CA3228773A1 (en) * 2021-08-12 2023-02-16 Gaurav KHARYA Chimeric antigen receptors (car) for b cell malignancies
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
CN115894704B (zh) * 2021-09-24 2023-12-26 四川大学 一种特异性靶向肿瘤EpCAM抗原的抗体及应用
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
US20250000976A1 (en) * 2021-10-07 2025-01-02 National Research Council Of Canada Anti-bcma single domain antibodies and therapeutic constructs
US20240417446A1 (en) 2021-10-26 2024-12-19 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CN114015674B (zh) 2021-11-02 2024-08-30 辉大(上海)生物科技有限公司 一种CRISPR-Cas12i系统
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
JP2024540275A (ja) 2021-11-04 2024-10-31 ヤンセン バイオテック， インク． Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN118556086A (zh) 2021-11-09 2024-08-27 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-3（gpc3）的含有igg4铰链的嵌合抗原受体及其用途
CN115466331B (zh) * 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
CA3241912A1 (en) * 2021-12-07 2023-06-15 Huafeng Wei Antibody binding to bcma and use thereof
CN114195898B (zh) * 2021-12-13 2022-10-28 南京凯地医疗技术有限公司 人源化抗cd33的单域抗体及其构建体制备方法和应用
CN118401561A (zh) * 2021-12-16 2024-07-26 浙江瑞加美生物科技有限公司 人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
JP2025508298A (ja) * 2021-12-29 2025-03-26 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー シングルドメイン高親和性抗体及びその使用方法
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
CN119156404A (zh) 2022-02-15 2024-12-17 美国政府(由卫生和人类服务部的部长所代表) 靶向gpc2的含有cd28铰链和跨膜结构的嵌合抗原受体及其用途
JP2025507678A (ja) 2022-02-28 2025-03-21 ヤンセン バイオテック， インク． Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法
CN114685664B (zh) * 2022-04-12 2023-10-20 内蒙古农业大学 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN119212724A (zh) * 2022-05-09 2024-12-27 上海先博生物科技有限公司 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Shenzhen Immunofoco Biotechnology Co., Ltd. Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
KR20250023513A (ko) * 2022-06-13 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 개선된 글리칸 의존성 면역치료 이중특이적 융합 단백질 및 키메라 항원 수용체
US12297285B2 (en) * 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN117343905A (zh) * 2022-06-27 2024-01-05 广西医科大学 靶向EGFRvⅢ分泌PD1单域抗体的CAR-T细胞及其制备方法和应用
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
US20260151429A1 (en) * 2022-08-25 2026-06-04 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
JP2026519263A (ja) 2022-10-26 2026-06-15 ノバルティス アーゲー レンチウイルス製剤
AU2023373360A1 (en) * 2022-11-02 2025-06-12 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy of multiple myeloma
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CN117069844B (zh) * 2022-12-06 2024-02-09 成都赛恩吉诺生物科技有限公司 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN116199781B (zh) * 2023-02-22 2025-07-18 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
WO2024206209A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
CN116640229B (zh) * 2023-04-10 2024-01-30 中国人民解放军总医院第五医学中心 一种低pH靶向性CAR-T细胞的构建及应用
CA3205511A1 (en) * 2023-04-19 2025-03-17 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2024240248A1 (zh) * 2023-05-24 2024-11-28 茂行制药(苏州)有限公司 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
CN116574181B (zh) * 2023-05-31 2026-06-09 华道(上海)生物医药股份有限公司 一种抗Glypican 3抗体及其应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117986387A (zh) * 2023-05-31 2024-05-07 四川大学华西医院 一种新型小型化car设计及制备方法和应用
CN116789859B (zh) * 2023-06-29 2024-02-23 徐州医科大学 一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
CN116949099B (zh) * 2023-07-12 2024-04-02 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
CN117024594B (zh) * 2023-09-21 2025-02-28 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
WO2025067472A1 (en) * 2023-09-27 2025-04-03 Nanjing Legend Biotech Co., Ltd. Methods of culturing gamma delta t cells
KR20260085124A (ko) 2023-10-05 2026-06-08 얀센 바이오테크 인코포레이티드 Car-t 세포 의약품의 생성을 위한 렌티바이러스 제조의 개선된 방법
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
CN120025440B (zh) * 2023-11-21 2026-07-17 南京融捷康生物科技有限公司 一种抗Nkp46的单域抗体及其用途
WO2025130984A1 (en) * 2023-12-20 2025-06-26 Overland Therapeutics (Us) Inc. Single domain antibodies for bcma
CN117821608A (zh) * 2023-12-28 2024-04-05 华道(上海)生物医药有限公司 一种检测car细胞的引物探针组合及其应用
KR102869233B1 (ko) * 2024-01-24 2025-10-15 주식회사 박셀바이오 Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
AU2025218081A1 (en) 2024-02-05 2026-07-16 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025193685A1 (en) 2024-03-12 2025-09-18 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
CN117866904B (zh) * 2024-03-12 2024-06-07 北京贝来药业有限公司 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025221781A2 (en) 2024-04-15 2025-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
US20260041768A1 (en) 2024-05-03 2026-02-12 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025232812A1 (en) * 2024-05-08 2025-11-13 Shanghai Vitalgen Biopharma Co., Ltd. Biomolecule conjugated lipid nanoparticles
WO2025235598A1 (en) 2024-05-09 2025-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
WO2025240496A1 (en) 2024-05-14 2025-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression
WO2026026960A1 (zh) * 2024-08-01 2026-02-05 原启生物科技(上海)有限责任公司 一种靶向bcma的人源化纳米抗体及其应用
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma
WO2026090579A1 (en) 2024-10-25 2026-04-30 Janssen Biotech, Inc. Methods of treating smoldering multiple myeloma with ciltacabtagene autoleucel
WO2026103881A1 (en) * 2024-11-15 2026-05-21 Nanjing Legend Biotech Co., Ltd. Bcma binding moieties and uses thereof
CN122071528A (zh) * 2024-11-22 2026-05-22 浙江纳米抗体技术中心有限公司 多特异性抗原结合分子及其应用
WO2026128545A1 (en) 2024-12-11 2026-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin-targeted car t cells with increased anti-tumor efficacy, persistence and resilience and use thereof for the treatment of mesothelin-positive cancers
WO2026158639A1 (en) * 2025-01-26 2026-07-30 Nanjing Legend Biotech Co., Ltd. Bcma binding moieties and uses thereof
CN120173114B (zh) * 2025-03-24 2025-09-26 广州泽朗生物医药科技有限公司 Cart细胞及其在制备抗癌症药物中的应用

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AU2474700A (en) 1998-12-01 2000-06-19 Genentech Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JP6636803B2 (ja) * 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
PL3177643T3 (pl) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
US11154615B2 (en) * 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021094037A (ja) * 2015-08-11 2021-06-24 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP7168173B2 (ja) 2015-08-11 2022-11-09 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2022183283A (ja) * 2015-08-11 2022-12-08 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2024032975A (ja) * 2015-08-11 2024-03-12 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
US12351638B2 (en) 2016-08-10 2025-07-08 Legend Biotech Usa Inc. Chimeric antigen receptors targeting BCMA and methods of use thereof

Also Published As

Publication number Publication date
CR20210225A (es) 2021-06-24
CY2024032I1 (el) 2026-02-25
PL3334765T3 (pl) 2026-04-27
WO2017025038A1 (en) 2017-02-16
RS67825B1 (sr) 2026-03-31
MX2018001739A (es) 2018-08-15
CL2021001706A1 (es) 2022-01-28
EP4755460A2 (en) 2026-06-10
KR102970371B1 (ko) 2026-05-29
PL4063397T3 (pl) 2024-11-18
MY199874A (en) 2023-11-27
PH12019500193A1 (en) 2019-07-29
CN122562971A (zh) 2026-08-14
EP3334765A1 (en) 2018-06-20
KR20240173368A (ko) 2024-12-11
SG10201913485QA (en) 2020-02-27
CN113185615A (zh) 2021-07-30
EP4424376B1 (en) 2026-02-18
NL301301I2 (nl) 2025-04-09
AU2025271439A1 (en) 2026-01-08
EP4063397B1 (en) 2024-06-19
SMT202600176T1 (it) 2026-07-16
CN117756941A (zh) 2024-03-26
CN113234173A (zh) 2021-08-10
US20210261675A1 (en) 2021-08-26
CN113234174A (zh) 2021-08-10
EP4755458A2 (en) 2026-06-10
ZA201800703B (en) 2018-12-19
UA125818C2 (uk) 2022-06-15
CN118085090A (zh) 2024-05-28
CN113234173B (zh) 2022-03-11
CY2024032I2 (el) 2026-02-25
US20180230225A1 (en) 2018-08-16
ES2984851T3 (es) 2024-10-31
PL4424376T3 (pl) 2026-07-06
CO2018001405A2 (es) 2018-11-22
FR24C1050I2 (fr) 2025-12-05
CN105384825B (zh) 2018-06-01
EP4755458A3 (en) 2026-08-12
MY188362A (en) 2021-12-03
DK3334765T3 (da) 2026-03-16
HRP20260300T1 (hr) 2026-04-24
LT3334765T (lt) 2026-03-25
JP7168173B2 (ja) 2022-11-09
IL294683A (en) 2022-09-01
CN109311999A (zh) 2019-02-05
MY192392A (en) 2022-08-18
IL257297B (en) 2022-08-01
JP2025159117A (ja) 2025-10-17
JP2024032975A (ja) 2024-03-12
SI4063397T1 (sl) 2024-10-30
EP3334765B1 (en) 2026-02-11
AU2016305075B2 (en) 2019-10-10
LTPA2024535I1 (enExample) 2024-12-27
CL2021001686A1 (es) 2022-01-28
NZ750366A (en) 2022-10-28
EP4424376A3 (en) 2024-12-04
AU2020200151A1 (en) 2020-01-30
CN109311999B (zh) 2026-06-09
LTC4063397I2 (enExample) 2026-05-25
CL2019000326A1 (es) 2019-10-04
IL264607A (en) 2019-02-28
DK4063397T3 (da) 2024-07-22
NO2024054I1 (no) 2024-12-10
PT4063397T (pt) 2024-07-29
IL257297A (en) 2018-03-29
AU2020200151B2 (en) 2022-03-17
SA518390904B1 (ar) 2023-02-22
UA130798C2 (uk) 2026-05-20
US10934363B2 (en) 2021-03-02
EA201890302A1 (ru) 2018-10-31
FIC20240042I1 (fi) 2024-12-11
SMT202400311T1 (it) 2024-11-15
CN113234174B (zh) 2024-01-09
SG11201900635QA (en) 2019-02-27
EP4424376C0 (en) 2026-02-18
LT4063397T (lt) 2024-09-25
CL2018000378A1 (es) 2018-08-17
JP2021094037A (ja) 2021-06-24
HUE064534T2 (hu) 2024-03-28
PH12018500295B1 (en) 2023-08-11
AU2022204180A1 (en) 2022-07-07
JP2026099826A (ja) 2026-06-18
AU2016305075A1 (en) 2018-03-08
RS68082B1 (sr) 2026-05-29
AU2020200151C1 (en) 2022-09-08
FI3334765T3 (fi) 2026-03-26
SMT202600116T1 (it) 2026-05-12
EP4063397A1 (en) 2022-09-28
FR24C1050I1 (fr) 2025-01-17
CN105384825A (zh) 2016-03-09
FI4063397T3 (fi) 2024-08-09
ES3068096T3 (es) 2026-05-27
CA2994579A1 (en) 2017-02-16
LT3896091T (lt) 2023-12-27
PT3334765T (pt) 2026-03-03
KR20180035918A (ko) 2018-04-06
SI3334765T1 (sl) 2026-05-29
EP4424376A2 (en) 2024-09-04
HUE067869T2 (hu) 2024-11-28
JP2022183283A (ja) 2022-12-08
JP2018525033A (ja) 2018-09-06
HRP20241057T1 (hr) 2024-11-08
CR20180153A (es) 2018-08-09
CA2994579C (en) 2023-07-11
PH12018500295A1 (en) 2021-05-10
MX2022015823A (es) 2023-01-24
SA519401072B1 (ar) 2024-02-01
ZA201807836B (en) 2019-08-28
NZ778787A (en) 2025-05-02
CO2019000946A2 (es) 2019-02-08
CN113185616A (zh) 2021-07-30
EP3334765A4 (en) 2019-05-08
BR112018002844A2 (pt) 2019-04-30
CN113185616B (zh) 2024-03-01
HUS2400044I1 (hu) 2025-01-28
ES3067089T3 (en) 2026-05-19
RS65866B1 (sr) 2024-09-30
NZ791176A (en) 2025-09-26

Similar Documents

Publication Publication Date Title
JP7843827B2 (ja) Ｂｃｍａを標的とするキメラ抗原受容体及びその使用方法
JP7168173B2 (ja) 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
HK40078340B (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
HK40078340A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
HK40102070A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HK40102069A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HK40064472B (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HK40103757A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HK40064472A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HK40115252A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
BR112019002687B1 (pt) Receptores de antígeno quimérico que direcionam bcma, ácido nucleico isolado, vetor, célula efetora imune engenheirada e composição farmacêutica compreendendo a célula efetora imune engenheirada
BR122024003787A2 (pt) Receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
EA052418B1 (ru) Лентивирусные векторы, содержащие их аутологичные сконструированные человеческие иммунные эффекторные клетки, фармацевтические композиции с этими клетками и их применения
EA047388B1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
EA046661B1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200428

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210325

R150 Certificate of patent or registration of utility model

Ref document number: 6859347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250